Daratumumab;达雷木单抗
产品简介:
Daratumumab is a recombinant IgG1k monoclonal antibody that binds to CD38 and leads to cell apoptosis. Daratumumab was granted orphan drug designation for the treatment of multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
分子式:C6466H9996N1724O2010S42分子量:145.39KD
产品形式:蛋白原液。每种装于冻存管中,单抗质量为标示数量1mg或者5mg,体积根据其浓度不同略有不同。
质量标准:
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test:…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件:
-70 ± 15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
运输条件:
干冰运输
- 使用建议:
-
- meilunbio提供的产品为蛋白原液形式。每种装于冻存管中,单抗质量为标示数量1mg或者5mg,体积根据其浓度不同略有不同。
- 使用前可以根据自己实验需求进行稀释,溶剂建议用去离子无菌水(meilunbio货号MA0028,去离子无菌水(细胞培养用水))或者PBS(meilunbio货号MA0015,PBS(1X),细胞培养级)。
- 不建议使用含有防腐成分的稀释液进行稀释,会增加细胞或者动物毒性。
- 稀释前,计算加入多少体积溶剂,请参考购买批次质检单上蛋白浓度,或者询问我司;举例,质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/mL;对应5MG包装的蛋白原液体积为5mg(质量)/50mg/mL(浓度)=0.1mL;实验需求蛋白浓度为10mg/mL, 需要稀释倍数为 50/10=5, 则需要加入0.4mL,即400ul PBS或者无菌去离子水即可。
- 若给药量为固定质量值,比如单次给药0.5mg,对应蛋白原液给药体积为10ul,建议稀释后,提高给药体积降低误差,因为注射器或者移液器吸头残留会影响实验效果。
- 稀释后的蛋白溶液,可于2-8度冷藏避光保存不超过2周,不建议长期储存。
- 避免反复冻融,每次冻融蛋白活性会降低约5%左右。
生物活性(仅来自于公开文献,不保证其有效性)
描述 | Daratumumab is a recombinant IgG1k monoclonal antibody that binds to CD38 and leads to cell apoptosis. Daratumumab was granted orphan drug designation for the treatment of multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. |
---|---|
靶点 | CD38 |
Application | antitumor agent |
用途及描述:
仅供科研,严禁用于人体(For R&D Only)
产品编号 | 品名 | Target |
---|---|---|
MB2806 | aflibercept | VEGFR |
MB2786 | Alemtuzumab | CD52 |
MB2787 | Alirocumab | PCSK9 |
MB2789 | Avelumab | PDL-1 |
MB2790 | Atezolizumab | PDL-1 |
MB2791 | Bevacizumab | VEGF |
MB2792 | Cetuximab | EGFR |
MB2784 | Adalimumab | TNF-α |
MB2794 | Denosumab | RANK Ligand |
MB2023 | Eculizumab | 补体蛋白(C5) |
MB2795 | Etanercept | TNF |
MB2797 | Evolocumab | PCSK9 |
MB2773 | Infliximab | TNF-α |
MB2769 | Ipilimumab | CTLA-4 |
MB2772 | Matuzumab | EGFR |
MB2766 | Mepolizumab | IL-5 |
MB2767 | Nivolumab | PD-1 |
MB2774 | Obinutuzumab | CD20 |
MB2776 | Ofatumumab | CD20 |
MB2777 | Omalizumab | IgE |
MB2781 | Panitumumab | EGFR |
MB2761 | Pembrolizumab | PD-1 |
MB2762 | Pertuzumab | HER2 |
MB2763 | Ranibizumab | VEGFR |
MB2938 | Ramucirumab | VEGFR |
MB2749 | Rituximab | CD20 |
MB2757 | Secukinumab | IL-17 |
MB2751 | Tocilizumab/Atlizumab | IL-6 receptor |
MB2753 | Trastuzumab | ErbB2 |
MB2758 | Ustekinumab | IL-12 |